NAMS
NewAmsterdam Pharma Company NV

453
Mkt Cap
$4.38B
Volume
1.31M
52W High
$41.47
52W Low
$14.06
PE Ratio
-18.47
NAMS Fundamentals
Price
$37.71
Prev Close
$38.62
Open
$39.57
50D MA
$33.71
Beta
0.80
Avg. Volume
1.28M
EPS (Annual)
-$2.56
P/B
5.86
Rev/Employee
$670,044.12
Loading...
Loading...
News
all
press releases
Letko Brosseau & Associates Inc. Invests $213,000 in NewAmsterdam Pharma Company N.V. $NAMS
Letko Brosseau & Associates Inc. bought a new stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) during the 2nd quarter, according to its most recent filing with the SEC...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Up 7% - Time to Buy?
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 7% - Here's Why...
MarketBeat·5d ago
News Placeholder
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down - Here's What Happened
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down - Here's What Happened...
MarketBeat·9d ago
News Placeholder
Research Analysts Offer Predictions for NAMS FY2026 Earnings
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) - Stock analysts at Cantor Fitzgerald lowered their FY2026 EPS estimates for shares of NewAmsterdam Pharma in a report issued on Thursday...
MarketBeat·11d ago
News Placeholder
FY2025 EPS Estimates for NAMS Decreased by Leerink Partnrs
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) - Investment analysts at Leerink Partnrs cut their FY2025 EPS estimates for NewAmsterdam Pharma in a research report issued on Wednesday...
MarketBeat·11d ago
News Placeholder
HC Wainwright Has Negative Outlook of NAMS FY2025 Earnings
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) - Stock analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of NewAmsterdam Pharma in a report...
MarketBeat·11d ago
News Placeholder
William Blair Has Negative Estimate for NAMS FY2025 Earnings
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) - Investment analysts at William Blair reduced their FY2025 earnings estimates for NewAmsterdam Pharma in a research report issued to...
MarketBeat·11d ago
News Placeholder
HC Wainwright Has Optimistic Outlook of NAMS FY2027 Earnings
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) - Equities research analysts at HC Wainwright lifted their FY2027 earnings per share (EPS) estimates for shares of NewAmsterdam Pharma in...
MarketBeat·12d ago
News Placeholder
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
Royal Bank Of Canada increased their price target on NewAmsterdam Pharma from $39.00 to $44.00 and gave the company an "outperform" rating in a research note on Thursday...
MarketBeat·14d ago
News Placeholder
NewAmsterdam Pharma (NASDAQ:NAMS) Posts Earnings Results, Misses Estimates By $0.03 EPS
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.41) EPS for the quarter, hitting analysts' consensus estimates of...
MarketBeat·14d ago

Latest NAMS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.